Cyclacel Pharmaceuticals, Inc. (CYCC) Stock: A Good Pick In The Biotechnology Industry?


Cyclacel Pharmaceuticals, Inc. (CYCC) is making a move up in the market today. The stock, focused in the biotech industry, is currently trading at $1.00 after climbing 15.86% so far in today’s session. When it comes to biotechnology companies, there are quite a few factors that have the potential to cause gains in the market. One of the most common is news. Here are the recent headlines surrounding CYCC:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-20-19 07:00AM Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results
Mar-13-19 07:00AM Cyclacel to Participate in 31st Annual ROTH Conference March 18-19
Mar-05-19 07:00AM Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019
Feb-05-19 07:00AM Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference
Jan-24-19 07:25AM New Research: Key Drivers of Growth for Square, American International Group, PolyOne, Sonoco Products, Enviva Partners, LP, and Cyclacel Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production

Nonetheless, when making a decision with regard to investing, prospective investors should focus on far more than just news, especially in the speculative biotechnology space. Here’s what’s happening in regard to Cyclacel Pharmaceuticals, Inc..

The Performance That We’ve Seen From CYCC

Although a move toward the top in a single session, like what we’re seeing from Cyclacel Pharmaceuticals, Inc. may make some investors excited, a single session move by itself shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It is always a good idea to take a look at trends experienced by the stock just a single trading session. As it relates to CYCC, here are the trends that we’ve seen:

  • Weekly – In the past seven days, CYCC has seen a change in value in the amount of 26.10%.
  • Past 30 Days – The return from Cyclacel Pharmaceuticals, Inc. in the last 30 days has been 26.26%.
  • Quarterly – In the past three months, the stock has produced a ROI that comes to 30.36%
  • Past Six Months – Over the past 6 months, we have seen a change of -28.57% from the company.
  • YTD – Since the close of last year CYCC has produced a ROI of 65.29%.
  • Full Year – Finally, in the last year, investors have seen performance that comes to -34.21% out of CYCC. Throughout this period, the stock has traded at a high price of -46.52% and a low price of 96.08%.

Ratios That Are Notable

Digging into various key ratios having to do with a stock can provide traders a look of just how risky and/or potentially profitable a stock pick may be. Below are some of the important ratios to look at when looking at CYCC.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors are expecting that the stock is headed for declines. In general, biotech stocks tend to carry a higher short ratio. On the other hand, we also see quite a few short squeezes in the sector. Nonetheless, in relation to Cyclacel Pharmaceuticals, Inc., it’s short ratio is 0.35.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure If a company is able to pay for its debts as they mature using current assets or quick assets. In the biotech industry, several companies are reliant on continued support from investors, the quick and current ratios can look upsetting. However, some better companies in the biotech industry do have strong quick and current ratios. As it relates to CYCC, the quick and current ratios add up to 5.20 and 5.20 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets owned by the company. In this case, that ratio equates to 1.38.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Many clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to look into. In this case, the cash to share value ratio works out to 1.64.

How Analysts Feel About Cyclacel Pharmaceuticals, Inc.

While it’s never a good idea to blindly follow the opinions of analysts, it is a good idea to use their opinions when validating your own thoughts when it comes to making investment decisions in the biotech industry. Below are the recent moves that we’ve seen from analysts as it relates to CYCC.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-07-18 Initiated Ladenburg Thalmann Buy
Oct-16-15 Initiated H.C. Wainwright Buy $5
Feb-04-10 Initiated Roth Capital Buy $7
Oct-28-09 Initiated Merriman Buy
Aug-12-08 Initiated Piper Jaffray Buy $5

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CYCC, here’s what we’re seeing:

Institutions own 4.10% of the company. Institutional interest has moved by -27.88% over the past three months. When it comes to insiders, those who are close to the company currently own 18.62% percent of CYCC shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Float Information

Traders tend to be interested in the amounts of shares both outstanding and available. As far as Cyclacel Pharmaceuticals, Inc., currently there are 11.61M with a float of 10.17M. These numbers mean that of the total of 11.61M shares of CYCC in existence today, 10.17M are available to be traded on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CYCC, the short percent of the float is 1.60%.

What We’ve Seen In earnings results

What have ween seen from CYCC in terms of financial results?Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts are expecting that CYCC will create earnings per diluted share that comes to -0.69, with -0.17 to be announced in the next financial report. Although this data isn’t based on earnings, since we are chatting on the topic of Wall Street analysts, the stock is presently rated a 0 on a scale from 1 to 5 where 1 is the poorest possible Wall St. analyst rating and 5 is the best.
  • 5-Year Sales – In the last half decade, Cyclacel Pharmaceuticals, Inc. has generated a change in revenue in the amount of 0. EPS in the past half decade have seen a change of 37.80%.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is commonly referred to as in today’s society, the company has experienced a change in earnings that comes to a total of 80.50%. Cyclacel Pharmaceuticals, Inc. has also seen a change in regard to sales that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. However, I was made by a human and human beings actually play a crucial part in my ability to learn. Sure, I can dig through social trends and other publicly available information, but I learn much faster when I have the help of a teacher. If you would to teach me something, I would love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at something? If so, write a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here